Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial.

Christensen JF, Jones LW, Tolver A, Jørgensen LW, Andersen JL, Adamsen L, Højman P, Nielsen RH, Rørth M, Daugaard G.

Br J Cancer. 2014 Jul 8;111(1):8-16. doi: 10.1038/bjc.2014.273. Epub 2014 May 27.

2.

Resistance training does not protect against increases in plasma cytokine levels among germ cell cancer patients during and after chemotherapy.

Christensen JF, Tolver A, Andersen JL, Rørth M, Daugaard G, Hojman P.

J Clin Endocrinol Metab. 2014 Aug;99(8):2967-76. doi: 10.1210/jc.2013-4495. Epub 2014 Jul 22.

PMID:
25050898
3.
4.

Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Hartmann M; German Testicular Cancer Study Group.

J Clin Oncol. 2008 Jun 20;26(18):2966-72. doi: 10.1200/JCO.2007.12.0899. Epub 2008 May 5. Erratum in: J Clin Oncol. 2010 Mar 10;28(8):1439. Dosage error in article text.

6.

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).

Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JR, Bokemeyer C, Schmoll HJ.

Ann Oncol. 2011 May;22(5):1054-61. doi: 10.1093/annonc/mdq575. Epub 2010 Nov 8.

7.

Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.

Tryakin A, Fedyanin M, Kanagavel D, Fainstein I, Sergeev J, Polockij B, Matveev V, Zakharova T, Garin A, Tjulandin S.

Urology. 2011 Sep;78(3):620-5. doi: 10.1016/j.urology.2011.05.005. Epub 2011 Jul 20.

PMID:
21764427
8.
9.

Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.

Horwich A, Sleijfer DT, Fosså SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP.

J Clin Oncol. 1997 May;15(5):1844-52.

PMID:
9164194
10.

The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP).

Peckham MJ, Barrett A, Liew KH, Horwich A, Robinson B, Dobbs HJ, McElwain TJ, Hendry WF.

Br J Cancer. 1983 May;47(5):613-9.

11.

Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983.

de Wit R, Skoneczna I, Daugaard G, De Santis M, Garin A, Aass N, Witjes AJ, Albers P, White JD, Germa-Lluch JR, Marreaud S, Collette L.

J Clin Oncol. 2012 Mar 10;30(8):792-9. doi: 10.1200/JCO.2011.37.0171. Epub 2012 Jan 23.

12.

Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older.

Thomsen FB, Bandak M, Thomsen MF, Lauritsen J, Christensen IJ, Daugaard G.

Cancer. 2014 Jan 1;120(1):43-51. doi: 10.1002/cncr.28374. Epub 2013 Sep 24.

13.

High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).

Haugnes HS, Laurell A, Stierner U, Bremnes RM, Dahl O, Cavallin-Ståhl E, Cohn-Cedermark G.

Acta Oncol. 2012 Feb;51(2):168-76. doi: 10.3109/0284186X.2011.641507. Epub 2011 Dec 19.

PMID:
22175254
14.

Management of good risk germ-cell tumours.

Troost MM, Sternberg CN, de Wit R.

BJU Int. 2009 Nov;104(9 Pt B):1387-91. doi: 10.1111/j.1464-410X.2009.08864.x. Review.

15.

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).

Fosså SD, Paluchowska B, Horwich A, Kaiser G, de Mulder PH, Koriakine O, van Oosterom AT, de Prijck L, Collette L, de Wit R; EORTC GU Group.

Br J Cancer. 2005 Nov 28;93(11):1209-14.

16.

Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

Grimison PS, Stockler MR, Chatfield M, Thomson DB, Gebski V, Friedlander M, Boland AL, Houghton B, Gurney H, Rosenthal M, Singhal N, Kichenadasse G, Wong SS, Lewis CR, Vasey PA, Toner GC; Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

Ann Oncol. 2014 Jan;25(1):143-8. doi: 10.1093/annonc/mdt369.

18.

[BEP (bleomycin, etoposide, cisplatin) therapy for testicular tumors].

Mori Y, Shima H, Ihara H, Yabumoto H, Iwasaki A, Yoshioka M, Ikoma F.

Hinyokika Kiyo. 1992 Oct;38(10):1139-42. Japanese.

PMID:
1282774
19.

[Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I].

Hartmann M, Siener R, Krege S, Schmelz H, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Albers P; German Testicular Cancer Study Group.

Urologe A. 2009 May;48(5):523-8. doi: 10.1007/s00120-008-1927-7. German.

PMID:
19183929
20.

Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.

Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP; Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.

J Clin Oncol. 2008 Jan 20;26(3):421-7. doi: 10.1200/JCO.2007.13.8461.

Items per page

Supplemental Content

Write to the Help Desk